COMBINATION IRREVERSIBLE ELECTROPORATION AND ANTI-PD1 THERAPY REVERSES MDSC INDUCED IMMUNE-SUPPRESSIVE MICROENVIRONMENT IN HEPATOCELLULAR CARCINOMA.

被引：0
|
作者：
Huo, Jihui
Lei, Kai
Peng, Sui
Kuang, Ming
Dai, Zihao
Wang, Lina
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1550
引用
收藏
页码：S1725 / S1725
页数：1
相关论文
共 50 条
  • [21] Pathological evaluation of tumor immune microenvironment before first-line anti-PD1 plus anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma (HCC): Towards a prediction for treatment efficacy
    Chen, Jun
    Zhou, Mingzhen
    He, Xintao
    Pu, Xiaohong
    Wu, Hongyan
    Chen, Sidong
    Wang, Yang
    Jiao, Lei
    Liu, Baorui
    Shen, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] PKCα/JZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma
    Wei, Chuan-Yuan
    Zhu, Meng-Xuan
    Zhang, Peng-Fei
    Huang, Xiao-Yong
    Wan, Jin-Kai
    Yao, Xiu-Zhong
    Hu, Ze-Tao
    Chai, Xiao-Qiang
    Peng, Rui
    Yang, Xuan
    Gao, Chao
    Gao, Jian
    Wang, Si-Wei
    Zheng, Yi-Min
    Tang, Zheng
    Gao, Qiang
    Zhou, Jian
    Fan, Jia-Bin
    Ke, Ai-Wu
    Fan, Jia
    JOURNAL OF HEPATOLOGY, 2022, 77 (01) : 163 - 176
  • [23] YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment
    Xiaochen Yang
    Wing Lam
    Zaoli Jiang
    Fulan Guan
    Xue Han
    Rong Hu
    Wei Cai
    William Cheng
    Shwu-Huey Liu
    Peikwen Cheng
    Yuping Cai
    Nicholas J. W. Rattray
    Caroline H. Johnson
    Lieping Chen
    Yung-Chi Cheng
    Scientific Reports, 11
  • [24] Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
    Kang, Xindan
    Wang, Jing
    Kang, Xue
    Bai, Li
    BMC CANCER, 2023, 23 (01)
  • [25] GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
    Rong, Dawei
    Wang, Yuliang
    Liu, Li
    Cao, Hengsong
    Huang, Tian
    Liu, Hanyuan
    Hao, Xiaopei
    Sun, Guangshun
    Sun, Guoqiang
    Zheng, Zhiying
    Kang, Junwei
    Xia, Yongxiang
    Chen, Ziyi
    Tang, Weiwei
    Wang, Xuehao
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (02)
  • [26] Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
    Xindan Kang
    Jing Wang
    Xue Kang
    Li Bai
    BMC Cancer, 23
  • [27] Pan-TGF-β inhibition with PD-1 blockade as a combination treatment strategy to augment anti-tumor immune response in hepatocellular carcinoma.
    Malkova, Natalia
    Theilhaber, Joachim
    Levit, Mikhail
    Tolstykh, Tatiana
    Hebert, Andrew
    Atchison, Kevin
    Maisonet, Adalis
    Sinicropi-Yao, Sara Sara
    Protopopov, Alexei
    Pollard, Jack
    Sidhu, Sukhvinder
    Lin, Tun Tun
    Pao, Lily
    Wiederschain, Dmitri
    Sharma, Sharad K.
    CANCER RESEARCH, 2021, 81 (13)
  • [28] YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment
    Yang, Xiaochen
    Lam, Wing
    Jiang, Zaoli
    Guan, Fulan
    Han, Xue
    Hu, Rong
    Cai, Wei
    Cheng, William
    Liu, Shwu-Huey
    Cheng, Peikwen
    Cai, Yuping
    Rattray, Nicholas J. W.
    Johnson, Caroline H.
    Chen, Lieping
    Cheng, Yung-Chi
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [29] Anti-PD1 antibody pucotenlimab in combination with bevacizumab or lenvatinib in a phase II study for the treatment of advanced hepatocellular carcinoma (aHCC).
    Zhao, Hong
    Zhou, Aiping
    Tu, Jianfei
    Bai, Yuxian
    Mao, Xianhai
    Song, Tianqiang
    Li, Bo
    Dai, Wenxiang
    Lv, Jing
    Wang, Jufeng
    Che, Xu
    Liu, Lianxin
    Zhang, Lianhai
    Wu, Wei
    Cai, Jianqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Triple combination therapy comprising angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.
    Zhang, Ti
    Zhang, Jinliang
    Zhang, Xihao
    Mu, Han
    Yu, Ge
    Xing, Wenge
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345